Jorden David Emerson, CEO and CFO of Nuo Therapeutics ($AURX), sold shares on the open market once in the last year, totaling $300,000. His most recent sale occurred on November 28, 2025. These sales rank 7,559th among nearly 12,000 insiders, where the average is $8.6 million across about six transactions. Emerson made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 1, 2026 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | M | Common Stock | 125000 | $0.40 | 2,071,755.0000 | 48,077,745 | 6.42% | 0.26% |
| Dec. 31, 2018 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | M | Option to purchase common stock | 125000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 1, 2026 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | F | Common Stock | 25381 | $1.97 | 2,046,374.0000 | 48,077,745 | 1.23% | 0.05% |
| Nov. 28, 2025 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | S | Common Stock | 200000 | $1.50 | 1,946,755.0000 | 48,077,745 | 9.32% | 0.42% |
| Aug. 1, 2025 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | M | Common Stock | 100000 | $0.40 | 2,075,358.0000 | 46,816,114 | 5.06% | 0.21% |
| Aug. 9, 2018 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | M | Option to purchase common stock | 192710 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 1, 2025 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | F | Common Stock | 21313 | $1.74 | 2,146,755.0000 | 46,816,114 | 0.98% | 0.05% |
| Aug. 1, 2025 | Nuo Therapeutics, Inc. | $AURX | JORDEN DAVID EMERSON | CEO/CFO | M | Common Stock | 92710 | $0.40 | 2,168,068.0000 | 46,816,114 | 4.47% | 0.20% |